Articles related to CAR T-CELL THERAPIES

The study’s findings highlight the complex interplay between CAR T cell therapy and cytokine signaling in AML treatment, suggesting new avenues for improving outcomes in this challenging disease.

Lisocabtagene maraleucel offers a new treatment option for patients with CLL who have progressed on both BTK and BCL2 inhibitors, addressing an important unmet need in this patient population.

Infections account for over 50% of nonrelapse deaths in CAR T-cell therapy patients, outweighing therapy-specific toxicities like ICANS and CRS.

Teclistamab, a BCMA bispecific antibody, demonstrates a promising 63% overall response rate in heavily pretreated R/R MM patients, with manageable toxicity compared to CAR T-cell therapy.

Secondary malignancies like indolent CD4+ CAR T-cell lymphoma can emerge after CAR T-cell therapy. This case highlights the importance of recognizing and thoroughly investigating these rare complications.

The occurrence of second tumors, such as T-cell lymphomas, post-CAR T-cell therapy is rare. The study identifies Epstein-Barr virus and mutant clonal hematopoiesis as potential factors but finds no evidence of oncogenic retroviral integration, providing valuable insights for clinical practice.